C-021

• Description :

  C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor with an IC50 of 18 nM[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  CCR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/c-021.html

• Purity :

  99.95

• Solubility :

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 80°C) |Ethanol : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  COC1=CC2=NC(N3CCC(N4CCCCC4)CC3)=NC(NC5CCCCCC5)=C2C=C1OC

• Molecular Formula :

  C27H41N5O2

• Molecular Weight :

  467.65

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Yokoyama K, et al. Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines. Bioorg Med Chem. 2009 Jan 1;17 (1) :64-73.|[2]Matthew McMillin, et al. Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline. J Neuroinflammation. 2014 Jul 10;11:121.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CCR4

• CAS Number :

  [864289-85-0]